Story perspectives

Study Links GLP-1 Drugs to Lower Colorectal Cancer Deaths

11/13/2025

50 12

Summary

Story summary

A University of California, San Diego study suggests GLP-1 receptor agonists may reduce mortality in colorectal cancer.
The study analyzed more than 6,800 patients and found a five-year death rate of 15.5% among users versus 37.1% among non-users.
Researchers note the study is observational and cannot prove causation, and they call for clinical trials to confirm potential benefits.
The findings were published on November 11, 2025, in Cancer Investigation.

1 of 1

Story summary

A University of California, San Diego study suggests GLP-1 receptor agonists may reduce mortality in colorectal cancer.
The study analyzed more than 6,800 patients and found a five-year death rate of 15.5% among users versus 37.1% among non-users.
Researchers note the study is observational and cannot prove causation, and they call for clinical trials to confirm potential benefits.
The findings were published on November 11, 2025, in Cancer Investigation.